UK drug bulletin evaluates the place of Sativex in MS spasticity treatment | Research

The takeaway

A UK drug evaluation bulletin reviewed Sativex evidence and noted it was licensed as add-on therapy for moderate-to-severe MS spasticity when other treatments have failed.

Read this if you want an independent perspective on where Sativex fits in MS treatment.

First cannabinoid preparation licensed for medical use in the UK

What the researchers found

This Drug and Therapeutics Bulletin evaluation reviewed the clinical evidence for Sativex (cannabis extract containing THC and CBD) for MS-related spasticity. MS affects about 60,000 people in England and Wales, with a lifetime UK risk of 1 in 1,000.

Spasticity was described as a common symptom requiring complex drug combinations that were often only partially effective with unacceptable side effects. Sativex was the first licensed cannabinoid preparation for medical use, approved specifically for patients with moderate-to-severe spasticity who had not responded adequately to other anti-spasticity medications.

The license required patients to demonstrate clinically significant improvement during an initial trial period before continuing treatment.

Why it matters

Independent drug evaluation bulletins help clinicians make prescribing decisions. This assessment from a source without industry ties provided a balanced perspective on where Sativex fits in the treatment pathway.

The numbers in context

MS affects ~60,000 people in England and Wales. UK lifetime risk: 1 in 1,000. Sativex licensed for moderate-to-severe spasticity after other treatments fail.

How the study worked

Drug evaluation review by the Drug and Therapeutics Bulletin, an independent UK publication that critically appraises medicines. Reviewed published clinical evidence for Sativex in MS spasticity.

What this study cannot tell us

Brief review format. Limited critical detail on the magnitude of treatment effects. The publication predated longer-term efficacy and safety data.

How to read the evidence

Independent drug evaluation review. Provides an unbiased assessment but is brief and does not add new data.

When this study was published

Published in 2012. Sativex prescribing in the UK has continued, though access varies by region.

The bigger picture

The licensing restriction to patients who failed other treatments and who demonstrated initial response reflected a pragmatic approach to a drug with modest average effect sizes but meaningful benefits for the subset who respond.

Questions still open

Is the initial trial period approach the most efficient way to identify responders? How does Sativex cost-effectiveness compare to other spasticity treatments? Should the licensing criteria be broader or narrower?

Common questions

Who can get Sativex in the UK?

Sativex was licensed for adults with moderate to severe MS spasticity who had not responded adequately to other anti-spasticity medications. Patients must show clinically significant improvement during an initial trial period to continue treatment.

Is Sativex the first choice for MS spasticity?

No. Sativex is positioned as add-on therapy after other treatments have been tried. It is reserved for patients whose spasticity is not adequately controlled by conventional medications.

Read the original research

What place for ▾ cannabis extract in MS?

Drug and therapeutics bulletin, 50(12), 141-4

View on PubMed ↗Publisher’s paper ↗

Citation

. (2012). What place for ▾ cannabis extract in MS?. Drug and therapeutics bulletin, 50(12), 141-4. https://doi.org/10.1136/dtb.2012.11.0150